TG Therapeutics (TGTX)
(Real Time Quote from BATS)
$25.74 USD
+0.49 (1.94%)
Updated Sep 19, 2024 11:57 AM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 161 - 180 ( 278 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q15 Results; Looking for Momentum into ASH; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q15 Results; Looking for Momentum into ASH; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Upcoming Clinical Milestones and 3Q15 Results Previews
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
SPA for "1303" Study; Approval Potential for Two Drugs and Two Settings
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Biotech Names for the Turn and the Long Haul
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q15 Results; GENUINE and Expanding Programs; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
We Believe Data Continue to Act as Strong GENUINE Proxy; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
The Opportunity for 1101,1202 in CLL: Efficacy - Safety Differentiation
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
ASCO Highlights Part 2-Our Thoughts from McCormick Place
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
An Enticing Threesome; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
ASCO Highlights Part 1-Our Thoughts from McCormick Place
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R